 Connection
Srikanth Vallurupalli to Risk Assessment
This is a "connection" page, showing publications Srikanth Vallurupalli has written about Risk Assessment.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.212 |
|
|
|
-
Ayoub K, Marji M, Ogunbayo G, Masri A, Abdel-Latif A, Ziada K, Vallurupalli S. Impact of Chronic Thrombocytopenia on?In-Hospital Outcomes After Percutaneous Coronary?Intervention. JACC Cardiovasc Interv. 2018 09 24; 11(18):1862-1868.
Score: 0.115
-
Salah HM, Al'Aref SJ, Khan MS, Al-Hawwas M, Vallurupalli S, Mehta JL, Mounsey JP, Greene SJ, McGuire DK, Lopes RD, Fudim M. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022 02 05; 21(1):20.
Score: 0.036
-
Mansour M, Radaideh Q, Alaiwah MN, Alnimer Y, Devabhaktuni SR, Dhar G, Vallurupalli S, Michos ED, Newby DE, Williams MC, Fudim M, Al'Aref SJ. Major adverse cardiac events in symptomatic women with non-obstructive CAD on coronary CTA: pooled analysis from PROMISE and SCOT-HEART. Int J Cardiovasc Imaging. 2022 Mar; 38(3):683-693.
Score: 0.036
-
Bhatti S, Watts E, Syed F, Vallurupalli S, Pandey T, Jambekar K, Mazur W, Hakeem A. Clinical and prognostic utility of cardiovascular magnetic resonance imaging in myeloma patients with suspected cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2016 Sep; 17(9):970-7.
Score: 0.025
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|